Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials

HIV Clinical Trials

Volumn 17, Issue 4, 2016, Pages 147-157

  Kim, Connie J ^a   Walmsley, Sharon L ^a,c   Raboud, Janet M ^a,c   Kovacs, Colin ^b   Coburn, Bryan ^a,c   Rousseau, Rodney ^c   Reinhard, Robert ^d   Rosenes, Ron ^e   Kaul, Rupert ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MAPLE LEAF MEDICAL CLINIC   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Disease Control Services   (Canada)

^e Health Consultant   (Canada)

Author keywords

Antiretroviral therapy; CD4 cells; Gastrointestinal health; HIV; Inflammation; Microbial translocation; Microbiome; Mucosal immunology; Natural health product; Placebo controlled; Probiotics; Randomized controlled trial

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VISBIOME;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE TRANSLOCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; INTESTINE FLORA; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; CLINICAL PROTOCOL; CLINICAL TRIAL; GASTROENTERITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; IMMUNOMODULATION; INTESTINE MUCOSA; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; MICROBIOLOGY; MUCOSAL IMMUNITY; PATHOLOGY; PERMEABILITY; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOLS; GASTROENTERITIS; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOMODULATION; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; PERMEABILITY; PROBIOTICS; RESEARCH DESIGN;

EID: 84976285778     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1080/15284336.2016.1184827     Document Type: Article

References (64)

1. A.I.van Sighem, L.A.Gras, P.Reiss, K.Brinkman, F.de Wolf, study Anoc. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527–1535.10.1097/QAD.0b013e32833a3946
2. J.Capeau. Premature aging and premature age-related comorbidities in HIV-infected patients: Facts and hypotheses. Clin Infect Dis. 2011;53:1127–1129.10.1093/cid/cir628
3. J.G.Caporaso, J.Kuczynski, J.Stombaugh,. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods. 2010;7:335–336.
4. S.G.Deeks. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118–123.
5. R.Rajasuriar, G.Khoury, A.Kamarulzaman, M.A.French, P.U.Cameron, S.R.Lewin. Persistent immune activation in chronic HIV infection AIDS. 2013;27:1199–1208.10.1097/QAD.0b013e32835ecb8b
6. N.R.Klatt, L.A.Canary, X.Sun,. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013;123:903–907.
7. J.D.Estes, L.D.Harris, N.R.Klatt,. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6:e1001052.10.1371/journal.ppat.1001052
8. C.J.Kim, A.Nazli, O.L.Rojas,. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol. 2012;5:670–680.10.1038/mi.2012.72
9. A.Nazli, O.Chan, W.N.Dobson-Belaire,. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010;6:e1000852.10.1371/journal.ppat.1000852
10. J.M.Brenchley, D.A.Price, T.W.Schacker,. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
11. J.M.Brenchley, T.W.Schacker, L.E.Ruff,. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–759.10.1084/jem.20040874
12. R.S.Veazey, M.DeMaria, L.V.Chalifoux,. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427–431.10.1126/science.280.5362.427
13. C.J.Kim, L.R.McKinnon, C.Kovacs,. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol. 2013;191:2164–2173.10.4049/jimmunol.1300829
14. D.Chege, P.M.Sheth, T.Kain,. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS. 2011;25:741–749.10.1097/QAD.0b013e328344cefb
15. E.O.Glocker, A.Hennigs, M.Nabavi,. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727–1735.10.1056/NEJMoa0810719
16. A.Symons, A.L.Budelsky, J.E.Towne. Are Th17 cells in the gut pathogenic or protective? Mucosal Immunol. 2012;5:4–6.10.1038/mi.2011.51
17. K.Kisand, A.S.Bøe Wolff, K.T.Podkrajšek,. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207:299–308.10.1084/jem.20091669
18. A.Cavani, D.Pennino, K.Eyerich. Th17 and Th22 in skin allergy. Chem Immunol Allergy. 2012;96:39–44.10.1159/000331870
19. I.Vujkovic-Cvijin, R.M.Dunham, S.Iwai,. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193–191.
20. S.M.Dillon, E.J.Lee, C.V.Kotter,. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014;7:983–994.
21. Z.Klase, A.Ortiz, C.Deleage,. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol. 2015;8:1009–1020.10.1038/mi.2014.128
22. N.G.Sandler, H.Wand, A.Roque,. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–790.10.1093/infdis/jiq118
23. S.Mehandru, M.A.Poles, K.Tenner-Racz,. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3:e484.10.1371/journal.pmed.0030484
24. M.Guadalupe, S.Sankaran, M.D.George,. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol. 2006;80:8236–8247.10.1128/JVI.00120-06
25. S.M.Fernandes, A.R.Pires, C.Ferreira,. Enteric mucosa integrity in the presence of a preserved innate interleukin 22 compartment in HIV type 1-treated individuals. J Infect Dis. 2014;210:630–640.10.1093/infdis/jiu126
26. G.Marchetti, A.Gori, A.Casabianca,. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS. 2006;20:1727–1736.10.1097/01.aids.0000242819.72839.db
27. P.W.Hunt, S.G.Deeks, B.Rodriguez,. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17:1907–1915.10.1097/00002030-200309050-00009
28. M.M.Lederman, L.Calabrese, N.T.Funderburg,. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204:1217–1226.10.1093/infdis/jir507
29. K.A.Lichtenstein, C.Armon, K.Buchacz,. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435–447.10.1086/652978
30. A.Zoufaly, A.Cozzi-Lepri, J.Reekie,. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One. 2014;9:e87160.10.1371/journal.pone.0087160
31. F.N.Engsig, R.Zangerle, O.Katsarou,. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58:1312–1321.10.1093/cid/ciu038
32. C.Tincati, E.Merlini, P.Braidotti,. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically-suppressive cART. AIDS. 2016;30:991–1003.
33. N.R.Klatt, N.T.Funderburg, J.M.Brenchley,. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21:6–13.10.1016/j.tim.2012.09.001
34. I.Bica, A.M.Tang, S.Skinner,. Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy. J Altern Complement Med. 2003;9:65–76.10.1089/107555303321222955
35. J.S.Josephs, J.A.Fleishman, P.Gaist, K.A.Gebo, Network HIVR. Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS. HIV Med. 2007;8:300–305.10.1111/hiv.2007.8.issue-5
36. Ontario HIV Treatment Network (OHTN). Priority populations. 2014; Accessed June, 2015. http://www.ohtn.on.ca/otw-portfolio/priority-populations/
37. L.Morelli, L.Capurso. FAO/WHO guidelines on probiotics. J Clin Gastroenterol. 2012;46:S1–S2.10.1097/MCG.0b013e318269fdd5
38. C.E.Zielinski, F.Mele, D.Aschenbrenner,. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature. 2012;484:514–518.10.1038/nature10957
39. I.I.Ivanov, K.Atarashi, N.Manel,. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485–498.10.1016/j.cell.2009.09.033
40. E.A.Mutlu, A.Keshavarzian, J.Losurdo,. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10:e1003829.10.1371/journal.ppat.1003829
41. T.M.Chapman, G.L.Plosker, D.P.Figgitt. VSL#3 probiotic mixture: A review of its use in chronic inflammatory bowel diseases. Drugs. 2006;66:1371–1387.10.2165/00003495-200666100-00006
42. A.M.Ortiz, Z.A.Klase, S.R.DiNapoli,. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. Mucosal Immunology. 2016;9:458–467.
43. H.Miller, R.Ferris, B.R.Phelps. The effect of probiotics on CD4 counts among people living with HIV: A systematic review. Benef Microbes. 2016;1–8.10.3920/BM2015.0163
44. J.Villar-García, J.J.Hernández, R.Güerri-Fernández,. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients. J Acquir Immune Defic Syndr. 2015;68:256–263.10.1097/QAI.0000000000000468
45. B.Stiksrud, P.Nowak, F.C.Nwosu,. Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. J Acquir Immune Defic Syndr. 2015;70:329–337.10.1097/QAI.0000000000000784
46. O.O.Yang, T.Kelesidis, R.Cordova, H.Khanlou. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial. AIDS Res Hum Retroviruses. 2014;30:988–995.10.1089/aid.2014.0181
47. G.d’Ettorre, G.Ceccarelli, N.Giustini,. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: Results of the “Probio-HIV” clinical trial. PLoS One. 2015;10:137200.
48. Services DoHaH. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 2015; Accessed June 18, 2015.
49. S.Eyerich, K.Eyerich, D.Pennino,. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573–3585.
50. E.J.Ciccone, S.W.Read, P.J.Mannon,. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 2010;3:172–181.10.1038/mi.2009.129
51. L.H.Kuller, R.Tracy, W.Belloso,. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.10.1371/journal.pmed.0050203
52. C.W.Teshima, J.B.Meddings. The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep. 2008;10:443–449.10.1007/s11894-008-0083-y
53. A.L.Kau, P.P.Ahern, N.W.Griffin, A.L.Goodman, J.I.Gordon. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474:327–336.10.1038/nature10213
54. C.M.Liu, B.J.Osborne, B.A.Hungate,. The semen microbiome and its relationship with local immunology and viral load in HIV infection. PLoS Pathog. 2014;10:e1004262.10.1371/journal.ppat.1004262
55. P.M.Sheth, D.Chege, L.Y.Shin,. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol. 2008;1:382–388.10.1038/mi.2008.23
56. M.R.Adams. Safety of industrial lactic acid bacteria. J Biotechnol. 1999;68:171–178.10.1016/S0168-1656(98)00198-9
57. S.P.Borriello, W.P.Hammes, W.Holzapfel,. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775–780.10.1086/cid.2003.36.issue-6
58. R.J.Boyle, M.L.Tang. The role of probiotics in the management of allergic disease. Clin Exp Allergy. 2006;36:568–576.10.1111/cea.2006.36.issue-5
59. S.Sankaran-Walters, M.Macal, I.Grishina,. Sex differences matter in the gut: Effect on mucosal immune activation and inflammation. Biol Sex Differ. 2013;4:10.10.1186/2042-6410-4-10
60. R.S.Remis, J.Liu. HIV/AIDS in Ontario: Preliminary Report, 2011. Toronto: University of Toronto; 2013.
61. P.W.Hunt, J.N.Martin, E.Sinclair,. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus–infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–1543.10.1086/jid.2003.187.issue-10
62. T.W.Schacker, C.Reilly, G.J.Beilman,. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS. 2005;19:2169–2171.10.1097/01.aids.0000194801.51422.03
63. Z.Liu, W.G.Cumberland, L.E.Hultin, H.E.Prince, R.Detels, J.V.Giorgi. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and Death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83–92.10.1097/00042560-199710010-00003
64. M.Paiardini, M.Müller-Trutwin. HIV-associated chronic immune activation. Immunol Rev. 2013;254:78–101.10.1111/imr.12079